Press Releases

BOSTON and SYDNEY – 10 May 2018 — GI Dynamics® Inc. (ASX: GID), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to announce the meta-analysis, “Effects of the Duodenal-Jejunal Bypass Liner on Glycemic Control in Type 2 Diabetic...

BOSTON and SYDNEY – 2 May 2018 — GI Dynamics® Inc. (ASX:GID), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, has received a binding commitment for a US$1,750,000 convertible note and warrant financing from Crystal Amber Fund Limited. The...

BOSTON and SYDNEY – 28 March 2018 – GI Dynamics® Inc. (ASX: GID), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, announced that it will release its 2017 Annual Report on Form 10K on or before 31 March EDT | 1 April AEST 2018. GI Dynamics...

BOSTON and SYDNEY — 8 March 2018 — GI Dynamics®, Inc. (ASX:GID), a medical device company that is developing EndoBarrier® is pleased to announce that it has today successfully completed the second tranche of the Placement (as detailed further in the 23 January 2018 announcement).  The closing of...

BOSTON and SYDNEY — 28 February 2018 — GI Dynamics®, Inc. (ASX:GID), a medical device company that is developing EndoBarrier®, held an adjourned Special Meeting on Tuesday, 27 February 2018 at 3:00pm Eastern Standard Time (being Wednesday, 28 February 2018 at 7:00am Australian Eastern Daylight...

BOSTON and SYDNEY — 07 February 2018— GI Dynamics®, Inc. (ASX:GID), a medical device company that is developing EndoBarrier® is pleased to confirm that, further to its announcement released on 23 January 2018, the attached proxy statement and notice of a special meeting of stockholders (Special...

BOSTON and SYDNEY — 23 January 2018— GI Dynamics®, Inc. (ASX:GID), a medical device company that is developing EndoBarrier® is pleased to announce that it has received binding commitments for a private placement of 58,780,619 CHESS Depositary Interests (CDIs) of the Company (representing 1,175,612...

BOSTON and SYDNEY — 15 January 2018— GI Dynamics®, Inc. (ASX:GID), a medical device company that is developing EndoBarrier® provides shareholders with a review of 2017 activities and its 2018 business outlook. GI Dynamics is preparing to submit an Investigational Device Exemption (IDE[1])...

BOSTON and SYDNEY — 24 November 2017 — GI Dynamics®, Inc. (ASX:GID), a medical device company that has commercialized EndoBarrier® in Europe, the Middle East and South America, announces today that the board of directors has received the resignation of GI Dynamics non-executive directors Anne...

BOSTON and SYDNEY – 17 November 2017 – GI Dynamics® Inc. (ASX: GID), a medical device company that has commercialized EndoBarrier® in Europe, the Middle East and South America for patients with type 2 diabetes and obesity, announces it will provide a corporate update and discuss 2017 third quarter...